Dr. Gottesman noted that paragraphs 6, 7, 8, and 9 in the 
containment section of the proposal dealing with animals had been 
inadvertently left out of her previous motion. Mr. Mitchell 
asked if there was objection to these paragraphs being added to 
the motion. There was no objection voiced by the committee. 
Dr. Miller said that there may be an oversight in the proposed 
Appendix Q. He said that paragraph 196 contained a requirement 
for marker sequences in transgenic animals. The current state- 
of-the-art did not guarantee that such sequences would be used in 
all experiments. The phrase "where practicable" should be 
inserted in paragraphs 196, 206, 236, and 278, in order to avoid 
an absolute requirement for marker sequences. Dr. Erickson 
disagreed and replied that in every case of a transgenic animal 
£he inserted gene in effect becomes the marker gene. 
Dr. Tolin pointed out that paragraphs 52, 53, and 70 of the 
proposal had not been included in any motion and contained 
language necessary to make the other proposed changes consistent 
with the NIH Guidelines. The Chair asked if there was objection 
to the inclusion of these paragraphs in Dr. Vidaver's motion; and 
in hearing none, the motion was amended to include those 
paragraphs . 
Dr. Musgrave said he had abstained because of the multitude of 
changes to the proposal. He asked if possibly the changes that 
were discussed could be incorporated in a document by Dr. Gart- 
land and brought back to the committee to ensure that it was the 
sense of the committee. The Chair said the committee had seemed 
substantially aware of the sense of all the changes. If there 
were any questions, the members of the working group would be 
consulted by Dr. Gartland. Dr. Gartland confirmed that if there 
were any questions as to the final wording that he would refer 
these matters back to the Working Group. 
Dr. Walters noted that RAC members are only temporarily on the 
committee, but Dr. Gartland and his staff had provided excellent 
support to the committee over the years. He formally thanked Dr. 
Gartland and his staff for their excellent support. 
IX. FUTURE MEETING DATES (tab 1296). 
Mr. Mitchell announced that the next three meetings would be 
February 1, June 3, and September 30, 1988. Dr. Gartland said 
that the September 30 meeting date had been changed to Monday, 
October 3, 1988. 
Having concluded the agenda and there being no further business 
to be discussed, Mr. Mitchell adjourned the committee at 3:37 
Recombinant DNA Research, Volume 13 
[79] 
